Literature DB >> 24755100

Single-position, minimally invasive Ivor Lewis oesophagectomy for lower thoracic oesophageal cancer.

Guofei Zhang1, Chengxiao Liang1, Gang Shen1, Ying Chai2.   

Abstract

Although several surgical approaches exist for lower thoracic oesophageal cancer, standardized techniques for minimally invasive oesophageal resection and intrathoracic anastomosis have not yet been established. Thus, optimization of the approach and identification of the ideal anastomosis technique are needed. Seven consecutive patients with lower thoracic oesophageal cancer were treated using a single-position, minimally invasive surgical technique with laparoscopy and thoracoscopy. In the present article, we describe this technique in detail and discuss the outcomes of these patients. No adverse events occurred intraoperatively, no failures in the intrathoracic oesophagogastrostomy were detected and favourable short-term outcomes were obtained. Thus, the procedure described is safe and technically feasible and appears to be promising as an alternative approach for the treatment of patients with lower thoracic oesophageal cancer.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Ivor Lewis oesophagectomy; Minimally invasive surgery; Oesophageal cancer

Mesh:

Year:  2014        PMID: 24755100     DOI: 10.1093/ejcts/ezu164

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  2 in total

1.  Minimally invasive esophageal resection and intrathoracic anastomosis for lower thoracic esophageal cancer with single position.

Authors:  Lufeng Zhao; Jianjun Ge; Wenshan Li; Yaping Luo; Ying Chai
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

2.  Staging resection of multiple primary esophageal cancer by endoscopic submucosal dissection and esophagectomy: A case report.

Authors:  Yufeng Yao; Yimin Wu; Ying Chai
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.